» Articles » PMID: 3712077

Scanning with Iodine-131 MIBG in Children with Solid Tumors: an Initial Appraisal

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 1986 May 1
PMID 3712077
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Twelve children with malignant disease in whom there was either a clinical, radiologic, or histologic differential diagnosis including neuroblastoma were investigated using iodine-131 metaiodobenzylguanidine (MIBG) scanning. In six children in whom a final diagnosis of neuroblastoma was substantiated, scans were positive; in five children with other malignancies, scans were negative. In one child, clinically and radiologically tumor free following excision on an abdominal neuroblastoma, scans were also negative. MIBG scanning proved of value as a discriminant of malignant undifferentiated tumors in children, and in the diagnosis and staging of neuroblastoma. During treatment, MIBG scans in two patients correlated with contemporaneous computed tomographic scans and may allow noninvasive monitoring of therapeutic response and completeness of surgical excision. Primary and recurrent abdominal tumors, and visceral, osseous, and marrow deposits were demonstrated using this technique.

Citing Articles

Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

Xia J, Zhang H, Hu Q, Liu S, Zhang L, Zhang A J Huazhong Univ Sci Technolog Med Sci. 2017; 37(5):649-660.

PMID: 29058276 DOI: 10.1007/s11596-017-1785-x.


Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.

Naranjo A, Parisi M, Shulkin B, London W, Matthay K, Kreissman S Pediatr Blood Cancer. 2011; 56(7):1041-5.

PMID: 21328522 PMC: 4581540. DOI: 10.1002/pbc.22991.


Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Matthay K, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V Br J Cancer. 2010; 102(9):1319-26.

PMID: 20424613 PMC: 2865749. DOI: 10.1038/sj.bjc.6605621.


Metastatic neuroblastoma: new abnormalities on bone scintigraphy may not indicate tumour recurrence.

Hall-Craggs M, Shaw D, Pritchard J, Gordon I Skeletal Radiol. 1990; 19(1):33-6.

PMID: 2326653 DOI: 10.1007/BF00197926.